Brind.

Alnylam and BridgeBio received label expansion approvals in the EU, while Pfizer's therapies compete in the ATTR-CM market.

7 reports, 5 independent Updated Aug 16
Gone quiet Reached 2 outlets in its first 24 hours
Reports
7
Developments
4
Repetition
43%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 5 independent outlets

Alnylam and BridgeBio received label expansion approvals in the EU, while Pfizer's therapies compete in the ATTR-CM market.

Who's involved

What this event is mainly about
Alnylam PharmaceuticalsPfizerBridgeBio

How it developed

Newest first. Tap a step to see who reported it.
  1. Market share gains and clinical failures complicate the competitive landscape in ATTR-CM.1 source
  2. Rival company gaining momentum in ATTR-CM market.1 source
  3. Stifel analyst commented on AstraZeneca's drug development in the ATTR-CM market.1 source
  4. Alnylam and BridgeBio expand market presence in EU; Pfizer competes in ATTR-CM.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • yahoo.com
  • fool.com
  • biopharmadive.com
  • ZacksCan Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? Alnylam Pharmaceuticals ALNY is a commercial-stage company that currently markets four drugs. The company first received regulatory a
  • BioPharma DiveNxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily Bio
  • BioPharma DiveAlnylam reaches new highs on strong sales of closely watched rare disease drug This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily B
1 more outlet ran the same wire story